Skip to main content
. 2023 Dec 24;9(3):526–548. doi: 10.1016/j.ekir.2023.12.019

Figure 5.

Figure 5

Proposed treatment algorithm for SGLT2i therapy in patients with CKD. AKI, acute kidney injury; BP, blood pressure; CKD, chronic kidney disease; DKA, diabetic ketoacidosis; eGFR, estimated glomerular filtration rate; GLP1-RA, glucagon-like peptide 1 receptor agonist; HbA1c, glycosylated Hemoglobin; RAASi, renin-angiotensin aldosterone system inhibitors; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylureas; UACR, urine albumin-to-creatinine ratio.

∗Refer to Box C for more details. Recreated with permission from Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi:10.1016/j.ekir.2022.04.09461; permission conveyed through Copyright Clearance Center, Inc.